Eli Lilly Q1 2024 10-Q Filed
Ticker: LLY · Form: 10-Q · Filed: 2024-04-30T00:00:00.000Z
Sentiment: neutral
Topics: 10-Q, financials, debt
TL;DR
Lilly's Q1 24 10-Q is in, showing financials and debt details. #LLY
AI Summary
Eli Lilly and Company (LLY) filed its 10-Q for the period ending March 31, 2024. The company reported its financial results for the first quarter of 2024, detailing its revenues, expenses, and other financial performance indicators. Specific details on debt instruments, such as "A718 Notes Due June 1 2025" and "A1.625 Notes Due June 2 2026", were also disclosed.
Why It Matters
This filing provides investors with Eli Lilly's latest financial performance and outlook, crucial for understanding the company's trajectory in the competitive pharmaceutical market.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Eli Lilly faces significant risks related to drug development, regulatory approvals, and market competition.
Key Players & Entities
- Eli Lilly & Co (company) — Filer
- 20240331 (date) — Period of Report
- 20240430 (date) — Filed as of Date
- 0000059478 (company) — Central Index Key
- A718 Notes Due June 1 2025 (dollar_amount) — Debt Instrument
- A1.625 Notes Due June 2 2026 (dollar_amount) — Debt Instrument
FAQ
What is the reporting period for this 10-Q filing?
The conforming period of report is 20240331, meaning the first quarter of 2024.
What is Eli Lilly & Co's Central Index Key (CIK)?
Eli Lilly & Co's Central Index Key is 0000059478.
What is the company's primary industry classification?
The company's Standard Industrial Classification is Pharmaceutical Preparations [2834].
What are some of the specific debt instruments mentioned in the filing?
The filing mentions several debt instruments including 'A718 Notes Due June 1 2025', 'A1.625 Notes Due June 2 2026', and 'A2.125 Notes Due June 3 2030'.
When was this 10-Q form filed?
This 10-Q form was filed on 20240430.
From the Filing
0000059478-24-000118.txt : 20240430 0000059478-24-000118.hdr.sgml : 20240430 20240430120451 ACCESSION NUMBER: 0000059478-24-000118 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 72 CONFORMED PERIOD OF REPORT: 20240331 FILED AS OF DATE: 20240430 DATE AS OF CHANGE: 20240430 FILER: COMPANY DATA: COMPANY CONFORMED NAME: ELI LILLY & Co CENTRAL INDEX KEY: 0000059478 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 350470950 STATE OF INCORPORATION: IN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-06351 FILM NUMBER: 24895249 BUSINESS ADDRESS: STREET 1: LILLY CORPORATE CTR STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 BUSINESS PHONE: 3172762000 MAIL ADDRESS: STREET 1: LILLY CORPORATE CENTER STREET 2: DROP CODE 1094 CITY: INDIANAPOLIS STATE: IN ZIP: 46285 FORMER COMPANY: FORMER CONFORMED NAME: LILLY ELI & CO DATE OF NAME CHANGE: 19941024 10-Q 1 lly-20240331.htm 10-Q lly-20240331 FALSE 2024 Q1 0000059478 12/31 TRUE FALSE http://fasb.org/us-gaap/2023#OtherLiabilitiesCurrent 211 0000059478 2024-01-01 2024-03-31 0000059478 us-gaap:CommonClassAMember 2024-01-01 2024-03-31 0000059478 lly:A718NotesDueJune12025Member 2024-01-01 2024-03-31 0000059478 lly:A1.625NotesDueJune22026Member 2024-01-01 2024-03-31 0000059478 lly:A2.125NotesDueJune32030Member 2024-01-01 2024-03-31 0000059478 lly:A625NotesDue2031Member 2024-01-01 2024-03-31 0000059478 lly:A500NotesDue2033Member 2024-01-01 2024-03-31 0000059478 lly:A6.77NotesDueJanuary12036Member 2024-01-01 2024-03-31 0000059478 lly:A1625NotesDue2043Member 2024-01-01 2024-03-31 0000059478 lly:A1700NotesDue2049Member 2024-01-01 2024-03-31 0000059478 lly:A1125NotesDue2051Member 2024-01-01 2024-03-31 0000059478 lly:A1375NotesDue2061Member 2024-01-01 2024-03-31 0000059478 2024-04-25 xbrli:shares iso4217:USD 0000059478 2023-01-01 2023-03-31 iso4217:USD xbrli:shares 0000059478 2024-03-31 0000059478 2023-12-31 0000059478 us-gaap:CommonStockMember 2022-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000059478 us-gaap:RetainedEarningsMember 2022-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2022-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000059478 us-gaap:TreasuryStockCommonMember 2022-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2022-12-31 0000059478 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0000059478 us-gaap:NoncontrollingInterestMember 2023-01-01 2023-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0000059478 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0000059478 us-gaap:TreasuryStockCommonMember 2023-01-01 2023-03-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0000059478 us-gaap:CommonStockMember 2023-03-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000059478 us-gaap:RetainedEarningsMember 2023-03-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2023-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000059478 us-gaap:TreasuryStockCommonMember 2023-03-31 0000059478 us-gaap:NoncontrollingInterestMember 2023-03-31 0000059478 us-gaap:CommonStockMember 2023-12-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000059478 us-gaap:RetainedEarningsMember 2023-12-31 0000059478 us-gaap:TrustForBenefitOfEmployeesMember 2023-12-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000059478 us-gaap:TreasuryStockCommonMember 2023-12-31 0000059478 us-gaap:NoncontrollingInterestMember 2023-12-31 0000059478 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0000059478 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0000059478 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-01 2024-03-31 0000059478 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0000059478 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 00000594